London, UK – 24 January 2024. A clinical validation study of Digistain in 801 patients with ER-positive, HER2-negative early breast cancer (median follow-up 12.7 years) was published in Breast Cancer Research and Treatment. The study reports the prognostic performance of the Digistain Prognostic Score; please see the publication for full results.

Digistain nominated for the EIT Awards 2026
Digistain has been nominated for the EIT Awards 2026 in the Venture Award category. The Venture Award recognises organisations combining strong commercial potential with meaningful